Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Other financing activities (2023 - 2025)

TriSalus Life Sciences (TLSI) has 3 years of Other financing activities data on record, last reported at $1.0 million in Q2 2025.

  • For Q2 2025, Other financing activities changed N/A year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.5 million, down 40.42%, while the annual FY2025 figure was $1.5 million, 40.42% down from the prior year.
  • Other financing activities reached $1.0 million in Q2 2025 per TLSI's latest filing, up from $520000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.6 million in Q3 2024 and bottomed at -$199633.0 in Q2 2023.
  • Average Other financing activities over 3 years is $691500.0, with a median of $359816.5 recorded in 2023.